HF
DMRA

HRT Financial’s Damora Therapeutics DMRA Stock Holding History

HRT Financial’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$484K Sell
18,638
-53,475
-74% -$1.29M ﹤0.01% 2711
2026
Q1 		$1.87M Buy
+72,113
New +$1.85M ﹤0.01% 1659

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM

HRT Financial's DMRA Position: Q2 2026 in Review

HRT Financial reduced its Damora Therapeutics (DMRA) stake by 74% in Q2 2026, selling an estimated $1.29M and leaving 18,638 shares worth $484K. The position accounts for ﹤0.01% of the portfolio, ranked #2711.

HRT Financial first reported a position in DMRA in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.87M in Q1 2026. 104 funds tracked by Wall St. Rank hold DMRA as of Q2 2026.

  • HRT Financial held 18,638 shares of Damora Therapeutics worth $484K as of Q2 2026.
  • HRT Financial sold 53,475 Damora Therapeutics shares in Q2 2026, an estimated $1.29M.
  • Damora Therapeutics made up ﹤0.01% of HRT Financial's portfolio in Q2 2026, its #2711 holding.
  • HRT Financial first reported a position in Damora Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • HRT Financial's Damora Therapeutics position peaked at $1.87M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Damora Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.